Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Oxford Biomedica (OXB)

Price 438.00p on 24-03-2023 at 18:12:24
Change -8.00p -1.79%
Buy 437.00p
Sell 434.50p
Buy / Sell OXB Shares
Last Trade: Unknown 1,811.00 at 438.00p
Day's Volume: 92,584
Last Close: 438.00p
Open: 439.00p
ISIN: GB00BDFBVT43
Day's Range 431.50p - 441.00p
52wk Range: 279.50p - 697.00p
Market Capitalisation: £422m
VWAP: 437.34595p
Shares in Issue: 96m

Recent Trades History Oxford Biomedica (OXB)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 1,811 438.00p Ordinary
Currency Conversion
OTC Trade
18:12:12 - 24-Mar-23
Unknown* 1,320 438.00p Ordinary
Currency Conversion
17:55:38 - 24-Mar-23
Unknown* 3,131 432.53p Ordinary
Currency Conversion
17:55:38 - 24-Mar-23
Unknown* 2,972 437.173p Ordinary
Currency Conversion
OTC Trade
17:54:40 - 24-Mar-23
Unknown* 2,410 435.806p Ordinary
Currency Conversion
OTC Trade
17:38:10 - 24-Mar-23
Unknown* 1,645 438.022p Ordinary
Currency Conversion
OTC Trade
17:09:56 - 24-Mar-23
Buy* 2,900 438.00p Ordinary
16:35:24 - 24-Mar-23
Buy* 2,900 438.00p Ordinary
16:35:19 - 24-Mar-23
Buy* 27,045 438.00p Suspected BUY Trade
16:35:03 - 24-Mar-23
Sell* 1,000 435.0012p Ordinary
16:27:19 - 24-Mar-23

Share Price History for Oxford Biomedica

Time period:
to
Date Open High Low Close Volume

Share News for Oxford Biomedica

SUMMARY: London listings with exposure to Silicon Valley Bank

13th Mar 2023 12:18

(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More

IN BRIEF: Oxford BioMedica confirms start date of Mathias as new CEO

20th Feb 2023 08:45

Oxford BioMedica PLC - Oxfordshire, England-based gene and cell therapy group - Says Frank Mathias, previously announced as the company's new chief executive officer, will officially join the firm on March 27. Mathias joins Oxford Biomedica from Rentschler Biopharma SE, where he has been CEO since 2016. Read More

IN BRIEF: Oxford Biomedica subsidiary signs deals with three US firms

14th Dec 2022 10:25

Oxford Biomedica PLC- Oxfordshire, England-based gene and cell therapy group - Says subsidiary Oxford Biomedica Solutions LLC has signed agreements with three unnamed US biotechnology firms. Under the agreements, the subsidiary will provide its full platform offering to support the new partners' pre-clinical gene therapy programmes. Read More

LONDON BRIEFING: UK inflation in November cools off record high

14th Dec 2022 07:53

(Alliance News) - Stocks in London are set to open lower on Wednesday, ahead of a key interest rate decision by the US Federal Reserve later in the day. Read More

IN BRIEF: Oxford BioMedica appoints Frank Mathias as new CEO

22nd Nov 2022 10:15

Oxford BioMedica PLC - Oxfordshire, England-based gene and cell therapy group - Appoints Frank Mathias as chief executive officer and board director, effective March 2023. Read More

FTSE 100 Latest
Value7,405.45
Change-94.15

Login to your account

Forgot Password?

Not Registered